Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 28Leukemia, Lymphocytic, Chronic, B-Cell 14Myelodysplastic Syndromes 6Waldenstrom Macroglobulinemia 5Lymphoma, B-Cell, Marginal Zone 5Burkitt Lymphoma 5Lymphoma, Mantle-Cell 4Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Recurrence 2Neoplasms 2Myeloproliferative Disorders 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Biphenotypic, Acute 2Leukemia 2Hematologic Neoplasms 2Blast Crisis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Follicular 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1GATA2 Deficiency 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 6fludarabine 4Standard of Care 4Practice Guidelines as Topic 3Mycophenolic Acid 3GSK2636771 3venetoclax 2trametinib 2talquetamab 2osimertinib 2dabrafenib 2X-Rays 2Whole-Body Irradiation 2Thiotepa 2Tacrolimus 2Specimen Handling 2Mesna 2Melphalan 2Magnetic Resonance Spectroscopy 2Filgrastim 2Biopsy 2ulixertinib 1trastuzumab biosimilar HLX02 1thymoglobulin 1sapanisertib 1ruxolitinib 1relatlimab 1plerixafor 1pertuzumab 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hematologic Neoplasms × venetoclax × 30 days × Clear all
NCT07007312 2026-06-03

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Kura Oncology, Inc.

Phase 3 Recruiting
1,300 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05753501 2026-06-02

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

AbbVie

Phase 1 Active not recruiting
135 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡